Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of
disease. Until recently, systemic treatment options that showed survival benefits in HCC …

Several anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies (Table 1) are currently being
investigated, alone and in combination, for the treatment of hepatocellular carcinoma (HCC) …

Hepatocellular Carcinoma (HCC) is one of the most common malignancies, and its
incidence and mortality are increasing worldwide. Cancer immunotherapy has …

The discovery of the immune checkpoint mechanism has contributed greatly to recent
advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody …

Primary liver cancer, mainly hepatocellular carcinoma (HCC), is the sixth most diagnosed
cancer and third leading cause of cancer-related death globally. Recently, immunotherapies …

Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …

Abstract Treatment of patients with hepatocellular carcinoma (HCC) in the advanced stage
remains a great challenge, with very few drugs approved. After decades of failure of immune …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death since
most patients are diagnosed at advanced stage and the current systemic treatment options …

Hepatocellular carcinoma (HCC) is one of the most common and fatal malignancies with an
alarming trend all around the world. Common therapeutic approaches in the early stage of …

Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with
advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20 …